Invivyd Inc. (IVVD) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Invivyd Inc. (NASDAQ: IVVD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.58 (-3.37% 1D, market cap $177.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IVVD ranks #851 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IVVD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $167.6M) and ABOS (Acumen Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per IVVD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832038), Invivyd Inc. generated $53.4M in revenue (+110.5% YoY), -$52.5M in net income, and -$58.3M in free cash flow against $276.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 36.2 (NEUTRAL RANGE)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IVVD currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.79) and Max Pain ($0.61) forces dealer call-delta covering toward $3.22.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Invivyd Inc. (IVVD) dropped -3.37% to $0.58, trading at 2% of its 52-week range ($0.53 – $3.07). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +110.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IVVD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IVVD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Invivyd Inc. (IVVD) ranks #851 by composite RQD confidence (30/100, grade E) and #593 by equity capitalization ($177.4M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with IVVD at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IVVD
ACTIVE
Invivyd Inc. | E | 30/100 | — | — | -35.0% | -3.37% | $177.4M | Benchmark Subject |
| IPHA Innate Pharma S.A. ADS | D+ | 52/100 | — | — | — | -2.67% | $167.6M | /ipha-vs-ivvd → |
| ABOS Acumen Pharmaceuticals Inc. | D- | 38/100 | — | — | -35.0% | -90.82% | $165.6M | /abos-vs-ivvd → |
| CGEN Compugen Ltd. | B+ | 78/100 | 5.5x | 87.3% | 85.0% | -2.94% | $193.0M | /cgen-vs-ivvd → |
| DTIL Precision BioSciences Inc. | E | 24/100 | — | — | -35.0% | -5.11% | $205.4M | /dtil-vs-ivvd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Invivyd Inc. (IVVD) reported GAAP revenue of $53.4M (+110.5% vs. FY2024 revenue of $25.4M ) , GAAP net income of -$52.5M, operating cash flow of -$58.1M, and free cash flow of -$58.3M (+65.8% YoY). On the balance sheet, IVVD closed FY2025 with $276.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $53.4M | -$52.5M | -$58.1M | -$58.3M | $276.9M | — |
| FY2024 (FY) | 2024-12-31 | $25.4M | -$169.9M | -$170.5M | -$170.6M | $129.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$198.6M | -$173.2M | -$173.2M | — | — |
As of 2026-11-02, Invivyd Inc. (NASDAQ: IVVD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.58 (-3.37% 1D, market cap $177.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IVVD ranks #851 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IVVD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $167.6M) and ABOS (Acumen Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per IVVD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832038), Invivyd Inc. generated $53.4M in revenue (+110.5% YoY), -$52.5M in net income, and -$58.3M in free cash flow against $276.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IVVD last traded at $0.58 (-3.37% on volume of 5,379,106 shares), positioning the stock -26.58% below its 50-day simple moving average ($0.79) and -50.00% below its 200-day simple moving average ($1.16). Across its 52-week range of $0.53 to $3.07, IVVD sits at the 2.0% percentile with a 14-day RSI of 36.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.65).
Why IVVD Stock dropped -3.37% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).